New 'In-Body' CAR-T therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07322159
Summary
This is a very early study to check the safety and first signs of effectiveness of a new type of CAR-T therapy called IASO206 for patients with multiple myeloma that has come back or stopped responding to standard treatments. The therapy works by genetically modifying a patient's own immune cells inside their body to target and attack the cancer cells. The study will enroll a small group of 12 patients to monitor for side effects and see if the treatment can reduce the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.